These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
410 related articles for article (PubMed ID: 18458272)
1. Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. Lanzkron S; Strouse JJ; Wilson R; Beach MC; Haywood C; Park H; Witkop C; Bass EB; Segal JB Ann Intern Med; 2008 Jun; 148(12):939-55. PubMed ID: 18458272 [TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea for the treatment of sickle cell disease. Segal JB; Strouse JJ; Beach MC; Haywood C; Witkop C; Park H; Wilson RF; Bass EB; Lanzkron S Evid Rep Technol Assess (Full Rep); 2008 Mar; (165):1-95. PubMed ID: 18457478 [TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Strouse JJ; Lanzkron S; Beach MC; Haywood C; Park H; Witkop C; Wilson RF; Bass EB; Segal JB Pediatrics; 2008 Dec; 122(6):1332-42. PubMed ID: 19047254 [TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148 [TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Nevitt SJ; Jones AP; Howard J Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137 [TBL] [Abstract][Full Text] [Related]
6. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383 [TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease. Tolu SS; Crouch A; Choi J; Gao Q; Reyes-Gil M; Ogu UO; Vinces G; Minniti CP Ann Hematol; 2022 Mar; 101(3):541-548. PubMed ID: 35039901 [TBL] [Abstract][Full Text] [Related]
8. Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease. Hoppe C; Vichinsky E; Quirolo K; van Warmerdam J; Allen K; Styles L J Pediatr Hematol Oncol; 2000; 22(4):330-4. PubMed ID: 10959903 [TBL] [Abstract][Full Text] [Related]
9. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586 [TBL] [Abstract][Full Text] [Related]
10. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease. de Montalembert M; Belloy M; Bernaudin F; Gouraud F; Capdeville R; Mardini R; Philippe N; Jais JP; Bardakdjian J; Ducrocq R; Maier-Redelsperger M; Elion J; Labie D; Girot R J Pediatr Hematol Oncol; 1997; 19(4):313-8. PubMed ID: 9256830 [TBL] [Abstract][Full Text] [Related]
11. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. Jayabose S; Tugal O; Sandoval C; Patel P; Puder D; Lin T; Visintainer P J Pediatr; 1996 Oct; 129(4):559-65. PubMed ID: 8859263 [TBL] [Abstract][Full Text] [Related]
12. Magnesium for treating sickle cell disease. Than NN; Soe HHK; Palaniappan SK; Abas AB; De Franceschi L Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011358. PubMed ID: 31498421 [TBL] [Abstract][Full Text] [Related]
13. Interventions for chronic kidney disease in people with sickle cell disease. Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087 [TBL] [Abstract][Full Text] [Related]
14. Magnesium for treating sickle cell disease. Than NN; Soe HHK; Palaniappan SK; Abas AB; De Franceschi L Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011358. PubMed ID: 28409830 [TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Charache S Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197 [TBL] [Abstract][Full Text] [Related]
16. Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries. Mulaku M; Opiyo N; Karumbi J; Kitonyi G; Thoithi G; English M Arch Dis Child; 2013 Nov; 98(11):908-14. PubMed ID: 23995076 [TBL] [Abstract][Full Text] [Related]